Author:
von Auw Nadine,Serfling Robert,Kitte Reni,Hilger Nadja,Zhang Chengkang,Gebhardt Clara,Duenkel Anna,Franz Paul,Koehl Ulrike,Fricke Stephan,Tretbar U. Sandy
Abstract
AbstractProcess development for transferring lab-scale research workflows to automated manufacturing procedures is critical for chimeric antigen receptor (CAR)-T cell therapies. Therefore, the key factor for cell viability, expansion, modification, and functionality is the optimal combination of medium and T cell activator as well as their regulatory compliance for later manufacturing under Good Manufacturing Practice (GMP). In this study, we compared two protocols for CAR-mRNA-modified T cell generation using our current lab-scale process, analyzed all mentioned parameters, and evaluated the protocols’ potential for upscaling and process development of mRNA-based CAR-T cell therapies.
Funder
German Federal Ministry of Education and Research
Fraunhofer-Institut für Zelltherapie und Immunologie IZI
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Watanabe, N., Mo, F. & McKenna, M. K. Impact of manufacturing procedures on CAR T cell functionality. Front. Immunol. 13, 876339. https://doi.org/10.3389/fimmu.2022.876339 (2022).
2. Dluczek, S., Tretbar, S., Fricke, S. & Köhl, U. CAR-T-Zellen: Update 2019. Transfusionsmedizin 9, 187–200. https://doi.org/10.1055/a-0833-2631 (2019).
3. Miliotou, A. N. & Papadopoulou, L. C. In vitro-transcribed (IVT)-mRNA CAR therapy development. Methods Mol. Biol. 2086, 87–117. https://doi.org/10.1007/978-1-0716-0146-4_7 (2020).
4. NIH U.S. National Library of Medicine. ClinicalTrials.gov. NCT02623582. https://clinicaltrials.gov/ct2/show/NCT02623582?term=NCT02623582&draw=2&rank=1.
5. NIH U.S. National Library of Medicine. ClinicalTrials.gov. NCT01897415. https://clinicaltrials.gov/ct2/show/record/NCT01897415?term=NCT01897415&draw=2&rank=1.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献